Changes in Macular and Peripheral Perfusion Following Anti-vascular Endothelial Growth Factor Treatment for Patients with Diabetic Retinopathy
Open Access
- 17 June 2019
- journal article
- Published by Scientific Scholar in American Journal of Ophthalmic Clinical Trials
- Vol. 2 (4), 4-7
- https://doi.org/10.25259/ajoct-3-2019
Abstract
Diabetic retinopathy (DR) is a common complication of diabetes mellitus. Imaging techniques such as the gold standard of fluorescein angiography (FA) and the recent advent of optical coherence tomography angiography (OCTA) have allowed for detailed visualization of the microvasculature to assess and quantify macular perfusion. The development of ultra-widefield FA (UWFA) has allowed clinicians to examine ischemia within the periphery. As our imaging and diagnostic methods continue to be refined, it is important to understand how to best utilize these technologies to characterize disease severity and determine how it can guide treatment and prognosis. With the increasing use of anti-vascular endothelial growth factor (VEGF) agents for the treatment of DR, we can characterize the changes in perfusion on the microvascular level. The focus of this review is to summarize and identify the changes in both macular and peripheral perfusion with anti-VEGF treatment for patients with DR utilizing FA, UWFA, and OCTA. There remains a need for more prospective, long-term clinical trials with controls to better understand the characterization of the retinal microvasculature using these imaging techniques. In clinical practice, physicians likely will need to utilize a multimodal imaging approach to appropriately characterize the degree and progression of ischemia in DR.Keywords
This publication has 37 references indexed in Scilit:
- Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular diseaseClinical Ophthalmology, 2013
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedemaBritish Journal of Ophthalmology, 2012
- Vision, Retinal Thickness, and Foveal Avascular Zone Size After Intravitreal Bevacizumab for Diabetic Macular EdemaAdvances in Therapy, 2012
- MACULAR PERFUSION DETERMINED BY FUNDUS FLUORESCEIN ANGIOGRAPHY AT THE 4-MONTH TIME POINT IN A PROSPECTIVE RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB OR LASER THERAPY IN THE MANAGEMENT OF DIABETIC MACULAR EDEMA (BOLT STUDY)Retina, 2010
- Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessmentEye, 2004
- Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scalesOphthalmology, 2003
- Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood– Retinal Barrier in Rabbits and PrimatesExperimental Eye Research, 1997
- How effective are treatments for diabetic retinopathy?JAMA, 1993
- Adverse reactions to fluorescein angiographyActa Ophthalmologica, 1986